Literature DB >> 6260212

Uptake of chylomicron remnants causes cholesterol accumulation in cultured human arterial smooth muscle cells.

C H Florén, J J Albers, E L Bierman.   

Abstract

Chylomicron remnants (Sf greater than 100) were prepared by treating human chylomicrons (Sf greater than 400) with human post heparin plasma. Chylomicron remnants recovered after 70-80% of chylomicron triacylglycerol was hydrolyzed, suppressed LDL-receptor activity and increased cell cholesterol esterification to the same extent as did LDL when added to cultured human arterial smooth muscle cells at an equal cholesterol concentration. Cell cholesterol mass increased 36% after incubation with 25 micrograms LDL cholesterol/ml and 35% with 25 micrograms chylomicron-remnant cholesterol/ml. Addition of 30 microM chloroquine plus LDL or chylomicron remnants further increased cholesterol content of cells (74% and 87%, respectively) and caused a significant rise in cell esterified cholesterol (344% and 369%, respectively). Cholesterol content per unit of apolipoprotein B mass of remnants was 2-3-fold higher than that of LDL. Therefore, if lipoprotein particles were added at equivalent apolipoprotein B mass chylomicron remnants increased cell cholesterol content and cholesterol esterification and suppressed LDL receptor activity significantly more than did LDL. This suggests that an additional determinant, presumably apolipoprotein E, is important for receptor recognition of chylomicron remnants. These results may be relevant to the delivery of chylomicron-derived cholesterol to arterial cells proposed as a feature of atherogenesis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6260212     DOI: 10.1016/0005-2760(81)90219-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Postprandial plasma retinyl ester response is greater in older subjects compared with younger subjects. Evidence for delayed plasma clearance of intestinal lipoproteins.

Authors:  S D Krasinski; J S Cohn; E J Schaefer; R M Russell
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

2.  Lipoprotein lipase secretion by human monocytes and rabbit alveolar macrophages in culture.

Authors:  E M Mahoney; J C Khoo; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

3.  Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations.

Authors:  E Boerwinkle; S Brown; A R Sharrett; G Heiss; W Patsch
Journal:  Am J Hum Genet       Date:  1994-02       Impact factor: 11.025

Review 4.  Role of smooth muscle cells in the initiation and early progression of atherosclerosis.

Authors:  Amanda C Doran; Nahum Meller; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-02-14       Impact factor: 8.311

5.  Ultrastructural studies of the portal transport of fat in chickens.

Authors:  R Fraser; V R Heslop; F E Murray; W A Day
Journal:  Br J Exp Pathol       Date:  1986-12

6.  Accumulation of serum lipids by vascular smooth muscle cells involves a macropinocytosis-like uptake pathway and is associated with the downregulation of the ATP-binding cassette transporter A1.

Authors:  Jennifer Rivera; Anna K Walduck; Shane R Thomas; Elias N Glaros; Elizabeth U Hooker; Elizabeth Guida; Christopher G Sobey; Grant R Drummond
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-08-30       Impact factor: 3.000

Review 7.  The metabolic basis of familial hypercholesterolemia.

Authors:  N B Myant
Journal:  Klin Wochenschr       Date:  1983-04-15

8.  Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years.

Authors:  M S Weintraub; I Grosskopf; T Rassin; H Miller; G Charach; H H Rotmensch; M Liron; A Rubinstein; A Iaina
Journal:  BMJ       Date:  1996-04-13

Review 9.  Postprandial Hyperlipidemia and Remnant Lipoproteins.

Authors:  Daisaku Masuda; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2016-11-08       Impact factor: 4.928

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.